Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use.
about
Teratogenic mechanisms of medical drugsSystemic lupus erythematosus: strategies to improve pregnancy outcomesThe treatment of hypertension during pregnancy: when should blood pressure medications be started?Congenital urinary tract obstruction: the long view.Angiotensin-converting enzyme inhibition aggravates renal interstitial injury resulting from partial unilateral ureteral obstruction in the neonatal rat.Acute coronary syndrome in pregnancy.Inadvertent relaxation of the ductus arteriosus by pharmacologic agents that are commonly used in the neonatal periodEffects of captopril on the human foetal placental circulation: an interaction with bradykinin and angiotensin IThe effect of antihypertensive drugs on the fetus.Screening, prevention, counseling, and treatment for the complications of type II diabetes mellitus. Putting evidence into practiceThe safety of antihypertensives for treatment of pregnancy hypertension.Hypertension and the vascular patient.Early expression of all the components of the renin-angiotensin-system in human development.Renin angiotensin system in development of mice and menHypertension guidelines: thresholds, targets, and teratogenicityImproved pregnancy outcome in type 1 diabetic women with microalbuminuria or diabetic nephropathy: effect of intensified antihypertensive therapy?Reversible Fetal Renal Impairment following Angiotensin Receptor Blocking Treatment during Third Trimester of Pregnancy: Case Report and Review of the Literature.A Novel Mutation in a Japanese Family with X-linked Alport Syndrome.Cardiac drug use in pregnancy: safety, effectiveness and obstetric implications.Short- and long-term strategies for the management of hypertensive disorders of pregnancy.Therapeutic management of type 1 diabetes before and during pregnancy.Acute coronary syndrome in pregnant women.Renal interstitial hyaluronan: functional aspects during normal and pathological conditions.Managing type 1 diabetes mellitus in pregnancy--from planning to breastfeeding.A complicated role for the renin-angiotensin system during pregnancy: highlighting the importance of drug discovery.A role for the extracellular matrix component hyaluronan in kidney dysfunction during ACE-inhibitor fetopathy.Factors associated with a vicious cycle involving a low nephron number, hypertension and chronic kidney disease.In Utero Origins of Hypertension: Mechanisms and Targets for Therapy.Acute kidney injury in the fetus and neonate.Adverse effects of the angiotensin-converting enzyme inhibitors.Peripartum Cardiomyopathy: Do Exosomes Play a Role?Renin-Angiotensin System Blocker Fetopathy.Antihypertensive drugs and the risk of congenital anomalies.Renal haemodynamics and function in weanling rats treated with enalapril from birth.(-)-Epigallocatechin-3-gallate inhibits human angiotensin-converting enzyme activity through an autoxidation-dependent mechanism.Susceptibility in utero and upon neonatal exposure.Purinergic P2Y6 receptors heterodimerize with angiotensin AT1 receptors to promote angiotensin II-induced hypertension.Malignant primary hypertension in pregnancy treated with lisinopril.The ontogeny of human pulmonary angiotensin-converting enzyme and its aberrant expression may contribute to the pathobiology of bronchopulmonary dysplasia (BPD)
P2860
Q22337136-AA3F2458-B81E-4F2E-BA94-F3B433A82056Q26741149-53E5577A-C6DE-4901-83F4-B1240390EB36Q26994764-F02C146C-2DC5-42EA-A637-791A54D1EB04Q27009005-897B3954-2A56-4D24-8AEB-7A890FAD71A6Q30442136-8593F73D-F47C-425A-81E8-D44E2C6E4E6BQ33860225-988FE392-B825-4ED9-998C-C8563B53A65EQ34061751-0416059A-6669-4E53-8D04-8470AB698FF7Q34347217-6618DD26-AECA-4A33-9E02-063EBF6E26DDQ34705302-E150278F-F342-40C1-82ED-35711C70A5F3Q34753635-74D0EFBC-AB9C-4A7D-9B85-BCF31149356FQ35609745-B58B252D-920E-4095-A5E2-15DE36E3CF92Q35738465-7512C79F-07F5-4175-B375-5F0E24245051Q35782663-D06FFEDB-2009-4CEA-B4A7-6284EDFDE847Q35782695-737D69B5-0912-4A60-92C7-7EA0B171D347Q36793874-B60CAB07-586E-4373-8F31-BCF390925BA9Q37022854-E45A96B0-C10B-4661-B5CC-E744466FC35AQ37273818-E5C7612F-ED2F-447F-974F-771685617312Q37383185-4DC63AAF-53E1-44A1-89F8-0F6B604E9C2EQ37642833-23D19884-0C76-4D9A-B0FF-E2517A670679Q37642835-812CDD28-6511-4F8C-B4D2-55696E0C6274Q37844162-8AD467EC-AF5E-4099-9ECF-AA4AA0EA96E1Q37868582-917FA78A-C6FD-4C1C-AC2E-CC0DF0227A52Q38003572-7AF0846D-873E-4232-BFD7-DAE7CE0962D2Q38042326-5600F86F-1C2F-49F1-B237-14C445E548E4Q38126570-1D801C22-BA53-40B5-B503-00113E1D254CQ38323949-B95EC320-68CB-4DC0-86CA-0C2456A3E120Q38530387-10CDE029-D993-4F3E-9881-80EAAE773389Q38737743-7DE458A9-7B61-4AB7-B700-0F8F6AED8C54Q39062499-023A1C97-09C2-416E-A624-33099AF6EE46Q41084284-3E611CB6-13F3-4897-B2FB-22DF6D674ECEQ41932356-25C04867-F838-44C0-9BE9-35F0573A4833Q43195095-EF33DC93-D977-4869-9904-414A42A9F8F1Q46254956-E50C052B-35A1-41DD-9E7E-99A3FC099B37Q46712862-A52B6508-8DA4-469C-9FB7-84979D38D09AQ50980349-8FC870D3-AB24-4AE7-9667-C244149427BDQ52187409-26F811CF-6B60-46E8-BDA3-337CB224A1CFQ52667266-3A0B3BE6-ABF6-471D-9189-D6F990A2FD86Q52864492-3CF371DF-0988-4772-A41C-C05E568D5082Q58197750-12A9FB56-0D09-45D6-964B-EE69ABEA08D6
P2860
Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Risks of angiotensin-convertin ...... , and recommendations for use.
@en
type
label
Risks of angiotensin-convertin ...... , and recommendations for use.
@en
prefLabel
Risks of angiotensin-convertin ...... , and recommendations for use.
@en
P2093
P1476
Risks of angiotensin-convertin ...... , and recommendations for use.
@en
P2093
P304
P356
10.1016/0002-9343(94)90172-4
P407
P577
1994-05-01T00:00:00Z